Yahoo Web Search

Sign In

Search results

  1. sg.linkedin.com › posts › mametz_we-are-proud-of-our-work-toMartin Metz’s Post - LinkedIn

    Martin Metz Chief Innovation Officer at eSentio Technologies 1y Report this post We are proud of our work to bring up -to-date research to the CIO community through ...

  2. Images

    • Martin Metz, GRÜNE, Rhein-Sieg-Kreis V, Landtagswahl - Kandidat:innen ...
    • Infos über Martin – Martin Metz
    • Prof. Dr. med. Martin Metz: Institute of Allergology - Charité ...
    • Martin Metz | OSOBNOSTI.CZ
    • Martin Metz's Biography - The Voter's Self Defense System - Vote Smart
    • Martin Metz – Espresso Tutorials

    View all

  3. www.researchgate.net › profile › Martin-Metz-3Martin METZ | Professor | Charité Universitätsmedizin Berlin,...

    Martin METZ | Cited by 19,139 | of Charité Universitätsmedizin Berlin, Berlin (Charité) | Read 396 publications | Contact Martin METZ

  4. www.imdb.com › name › nm3763806Martin Metz - IMDb

    Martin Metz is known for Good Luck to You, Leo Grande (2022), Paws of Fury: The Legend of Hank (2022) and Mandy (2018).

    • Additional Crew, Producer, Production Manager
    • Martin Metz

  5. www.nerretherapeutics.com › team › martin-metzProfessor Martin Metz - NeRRe Therapeutics

    Martin Metz is Professor of Dermatology with focus on pruritus research at the Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Germany. He received his medical education at the Free University of Berlin and the Humboldt University of Berlin.

  6. scholar.google.com › citations‪Martin Metz‬ - ‪Google Scholar‬

    Martin Metz. Charité - Universitätsmedizin Berlin. Verified email at charite.de. Mast cell Urticaria Pruritus. Articles Cited by Public access. Title. Sort.

  7. www.linkedin.com › in › mametzMartin Metz - Chief Innovation Officer - eSentio Technologies -...

    View Martin Metz’s profile on LinkedIn, the world’s largest professional community. Martin has 6 jobs listed on their profile.

    • eSentio Technologies

  8. pubmed.ncbi.nlm.nih.gov › 31577874Ligelizumab for Chronic Spontaneous Urticaria - PubMed

    Oct 3, 2019 · In this small and short trial, no safety concerns regarding ligelizumab or omalizumab emerged. Conclusions: A higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelizumab therapy of 72 mg or 240 mg than with omalizumab or placebo.